Nina Linde

Nina Linde

Auto-generated profile, based on publicly available information

Nina Linde

The healthcare business of Merck KGaA, Darmstadt, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
LSLuna De Sutter
Luna De Sutter
AWAgnieszka Wozniak
Agnieszka Wozniak
JVJasper Verreet
Jasper Verreet
UVUlla Vanleeuw
Ulla Vanleeuw
LCLore De Cock
Lore De Cock
PSPatrick Schöffski
Patrick Schöffski
Purpose: The majority of gastrointestinal stromal tumors (GIST) are driven by constitutively activated KIT/PDGFRA kinases and are susceptible to treatment with tyrosine kinase inhibitors. During treatment, most of these tumors will develop secondary mutations in KIT or PDGFRA inducing drug resistance, so there is an unmet need for novel therapies. We tested the efficacy of IDRX-42, a novel selective KIT inhibitor with high activity toward the most relevant KIT mutations, in 4 GIST xenograft models. Experimental Design: NMRI nu/nu mice were transplanted with patient-derived GIST xenograft models UZLX-GIST9 (KIT:p.P577del;W557LfsX5;D820G), UZLX-GIST2B (KIT:p.A502_Y503dup), UZLX-GIST25 (KIT:p.K642E), and the cell line–derived model GIST882 (KIT:p.K642E). Mice were treated daily with vehicle (control), imatinib (100 mg/kg), sunitinib (20 mg/kg), avapritinib (5 mg/kg), or IDRX-42 (10 mg/kg, 25 mg/kg). Efficacy was assessed by tumor volume evolution, histopathology, grading of histologic response, and IHC. The Kruskal–Wallis and Wilcoxon matched-pairs tests were used for statistical analysis, with P < 0.05 considered as significant. Results: IDRX-42 (25 mg/kg) caused tumor volume shrinkage in UZLX-GIST25, GIST882, and UZLX-GIST2B, with a relative decrease to 45.6%, 57.3%, and 35.1% on the last day as compared with baseline, and tumor growth delay (160.9%) compared with control in UZLX-GIST9. Compared with controls, IDRX-42 (25 mg/kg) induced a significant decrease in mitosis. In UZLX-GIST25 and GIST882 grade 2–4 histologic response with myxoid degeneration was observed in all IDRX-42 (25 mg/kg)-treated tumors. Conclusions: IDRX-42 showed significant antitumor activity in patient- and cell line–derived GIST xenograft models. The novel kinase inhibitor induced volumetric responses, decreased mitotic activity, and had antiproliferative effects. In models with KIT exon 13 mutation IDRX-42 induced characteristic myxoid degeneration.

30 December 2024 in Grassroots Journal of Natural Resources
Verified
Journal Article
Open access
NLNina Linde
Nina Linde
ABAnush Balian
Anush Balian
TSTatyana Shabatura
Tatyana Shabatura
IGInna Gryshova
Inna Gryshova
AYAlla Yakovenko
Alla Yakovenko
THTetiana Hnatieva
Tetiana Hnatieva
The depth of the ecological crisis raises the issue of implementing innovative solutions and technologies in waste management that align with the principles of the circular economy. This research explores the advantages of using artificial intelligence (AI) in waste management systems in Ukraine. The study employs methods of systems analysis, formalization, abstract and logical analysis, in addition to the linear trend method. A comparative analysis of waste management in Ukraine and EU countries was conducted. It was found that the waste generation level in Ukraine is 11.1 tons per person per year, compared to 4.8 tons in the EU. Only 8.24% of waste in Ukraine is sent for recycling, while this figure reaches 49.6% in the EU. The analysis revealed that insufficient infrastructure, poor-quality legislation, and the destruction caused by the war significantly affect waste management practices in Ukraine. An exhaustive review of current startups and technological solutions in waste management utilizing AI was conducted. The findings show that the implementation of AI in waste management can increase recycling rates by 20-30% and reduce operational costs by 10-15%. It is projected that by 2033, the global AI market for waste management will reach USD 18.2 billion, demonstrating an annual growth rate of 27.5%. The study concludes that applying AI in waste management in Ukraine could significantly reduce waste incineration and increase recycling rates to 70% by 2030, aligning with the goals of the National Waste Management Strategy.

30 December 2024 in Grassroots Journal of Natural Resources
Verified
Journal Article
Open access
NLNina Linde
Nina Linde
ABAnush Balian
Anush Balian
TSTatyana Shabatura
Tatyana Shabatura
IGInna Gryshova
Inna Gryshova
OPOlga Petrenko
Olga Petrenko
ASAlisa Shevchenko
Alisa Shevchenko
This study evaluates the potential of artificial intelligence (AI) and agritech solutions to drive sustainable development in Ukraine's agricultural sector during the post-war recovery period. Emphasizing high-potential technologies such as IoT-enabled precision farming and robotics, the research highlights their technical and commercial viability, as well as investment opportunities, in alignment with global trends. By employing systems analysis, formalization, and logical abstraction, the study identifies innovative solutions to enhance resource efficiency, minimize environmental impact, and promote economic growth. Key findings reveal that agritech serves as a critical enabler for rebuilding Ukraine’s agricultural infrastructure, creating a post-war model that balances economic and environmental priorities. Strengthening the integration of AI and advanced technologies will enhance the efficiency and productivity of farms, bolster Ukraine's global competitiveness, and deliver positive social outcomes, including fostering digital adoption in rural communities. These insights provide a roadmap for leveraging agritech to align with sustainable development goals while addressing local challenges.

28 February 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
CEChristina Esdar
Christina Esdar
NLNina Linde
Nina Linde
ABAndreas Blum
Andreas Blum
HSHanno Schieferstein
Hanno Schieferstein
CDChristine Drechsler
Christine Drechsler
ABAndree Blaukat
Andree Blaukat
Primary activating mutations in KIT (exon 9/11) are key driver alterations in about 80% of gastrointestinal stromal tumors (GIST). Imatinib, a small-molecule tyrosine kinase inhibitor, is used successfully as first-line therapy for patients with unresectable metastatic or recurrent GIST, but secondary resistance mutations in the KIT kinase domains frequently occur. Currently approved later-line therapies target these mutations incompletely with limited clinical benefit. M4205, a kinome-selective KIT inhibitor, was designed to address this high unmet medical need by inhibiting all relevant KIT driver and resistance mutations. Compared with imatinib, M4205 shows stronger antitumor activity in preclinical GIST models driven by oncogenic KIT driver mutations. M4205 demonstrates clinically relevant efficacy in a range of preclinical GIST models expressing different secondary KIT resistance mutations. The kinase selectivity profile of M4205 is superior to the registered standard of care and investigational agents. M4205, now IDRX-42, is currently being investigated in a phase I first-in-human study in participants with GIST.

1 October 2021 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
UGUlrich Grädler
Ulrich Grädler
MBMichael Busch
Michael Busch
BLBirgitta Leuthner
Birgitta Leuthner
MRMichael Raba
Michael Raba
LBLars Burgdorf
Lars Burgdorf
CEChristina Esdar
Christina Esdar